Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%
Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

At a Glance

Live Snapshot
Market Cap$357.74M
EPS0.1900
P/E Ratio55.84
Earnings Date

dmaa

Operating Income

Last Annual Value

-2.82M

3-Year CAGR

-1705%

5-Year CAGR

-467%

10-Year CAGR

-138%

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors Analysis of Operating Income

DMAA · NASDAQ
CompanyOperating Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
-2.82M
N/AN/AN/A 
-1.01M
N/AN/AN/A
0.00
N/AN/AN/A
-1.01M
N/AN/AN/A
-456.69K
N/AN/AN/A
-9.11M
N/AN/AN/A
-1.03M
N/AN/AN/A
-647.45K
N/AN/AN/A
-647.45K
N/AN/AN/A
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope

DMAA · NASDAQ

Our analysis suggests that DMAA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.61, this represents a potential HIDDEN relative to our calculated worth for Drugs Made In America Acquisition Corp. Ordinary Shares.

Intrinsic Value
Current Price: $10.61